AtaiBeckley Inc. Reports Q4 2025 Earnings and Progress on BPL-003 Phase 3 Trials

AtaiBeckley Inc. (NASDAQ: ATAI) Reports Q4 2025 Results and Advances BPL-003 Toward Phase 3

• AtaiBeckley Inc. (NASDAQ: ATAI) reported adjusted/non-GAAP EPS of approximately -$0.05 for Q4 2025, beating consensus estimates of -$0.12 (note: GAAP EPS was -$1.73 due to non-cash merger-related charges).
• Revenue was approximately $1.07 million, above prior-year levels but below some higher analyst expectations.
• ATAI maintains a strong cash position of ~$220.7 million (as of Dec 31, 2025), with runway into early 2029.

AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biotechnology company focused on innovative mental health treatments. Following its 2025 strategic combination and redomiciliation, the company is advancing key programs, including BPL-003 nasal spray for treatment-resistant depression (TRD).

Financial performance showed revenue growth to ~$1.07 million in Q4, with adjusted EPS beating estimates (though GAAP results reflected merger impacts). The company is on track to initiate a Phase 3 pivotal program for BPL-003 in Q2 2026, consisting of two trials (ReConnection-1 and ReConnection-2) targeting adults with TRD, following positive FDA End-of-Phase 2 feedback.

Despite ongoing unprofitability (negative P/E, negative operating cash flow), low debt and high liquidity support continued development. Other progress includes positive Phase 2a results for EMP-01 in Social Anxiety Disorder. The company discussed these updates during its Virtual Investor Day on March 6, 2026.